Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
PEG-modified drugs (recombinant proteins/polypeptides) refer to the formation of PEG-modified complexes by covalently linking polyethylene glycol molecules to recombinant proteins or polypeptide drugs. This modification can endow the drug with many beneficial properties, improving its pharmacological and biological properties.
PEG-modified drugs have the following advantages: improving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
The Global Info Research report includes an overview of the development of the PEG-modified Drugs (Recombinant Proteins-Polypeptides) industry chain, the market status of Nonmyeloid Malignancy (Jinyouli, Xin Rui Bai), Slow Growth in Children (Jinyouli, Xin Rui Bai), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of PEG-modified Drugs (Recombinant Proteins-Polypeptides).
Regionally, the report analyzes the PEG-modified Drugs (Recombinant Proteins-Polypeptides) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the PEG-modified Drugs (Recombinant Proteins-Polypeptides) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Jinyouli, Xin Rui Bai).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market.
Regional Analysis: The report involves examining the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to PEG-modified Drugs (Recombinant Proteins-Polypeptides):
Company Analysis: Report covers individual PEG-modified Drugs (Recombinant Proteins-Polypeptides) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards PEG-modified Drugs (Recombinant Proteins-Polypeptides) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Nonmyeloid Malignancy, Slow Growth in Children).
Technology Analysis: Report covers specific technologies relevant to PEG-modified Drugs (Recombinant Proteins-Polypeptides). It assesses the current state, advancements, and potential future developments in PEG-modified Drugs (Recombinant Proteins-Polypeptides) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
PEG-modified Drugs (Recombinant Proteins-Polypeptides) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe PEG-modified Drugs (Recombinant Proteins-Polypeptides) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PEG-modified Drugs (Recombinant Proteins-Polypeptides), with price, sales, revenue and global market share of PEG-modified Drugs (Recombinant Proteins-Polypeptides) from 2018 to 2023.
Chapter 3, the PEG-modified Drugs (Recombinant Proteins-Polypeptides) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PEG-modified Drugs (Recombinant Proteins-Polypeptides) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and PEG-modified Drugs (Recombinant Proteins-Polypeptides) market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of PEG-modified Drugs (Recombinant Proteins-Polypeptides).
Chapter 14 and 15, to describe PEG-modified Drugs (Recombinant Proteins-Polypeptides) sales channel, distributors, customers, research findings and conclusion.
PEG-modified drugs (recombinant proteins/polypeptides) refer to the formation of PEG-modified complexes by covalently linking polyethylene glycol molecules to recombinant proteins or polypeptide drugs. This modification can endow the drug with many beneficial properties, improving its pharmacological and biological properties.
PEG-modified drugs have the following advantages: improving drug solubility, increasing drug stability, prolonging blood drug half-life, reducing immunogenicity, and regulating drug release rate. PEG-modified drugs have been successfully used in many fields, such as antibody drugs, protein kinase inhibitors, peptide drugs, etc. They have better biocompatibility, stability and controlled release properties, which provide a new way to improve the efficacy of drugs and obtain better therapeutic effects.
The Global Info Research report includes an overview of the development of the PEG-modified Drugs (Recombinant Proteins-Polypeptides) industry chain, the market status of Nonmyeloid Malignancy (Jinyouli, Xin Rui Bai), Slow Growth in Children (Jinyouli, Xin Rui Bai), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of PEG-modified Drugs (Recombinant Proteins-Polypeptides).
Regionally, the report analyzes the PEG-modified Drugs (Recombinant Proteins-Polypeptides) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global PEG-modified Drugs (Recombinant Proteins-Polypeptides) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the PEG-modified Drugs (Recombinant Proteins-Polypeptides) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Jinyouli, Xin Rui Bai).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market.
Regional Analysis: The report involves examining the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to PEG-modified Drugs (Recombinant Proteins-Polypeptides):
Company Analysis: Report covers individual PEG-modified Drugs (Recombinant Proteins-Polypeptides) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards PEG-modified Drugs (Recombinant Proteins-Polypeptides) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Nonmyeloid Malignancy, Slow Growth in Children).
Technology Analysis: Report covers specific technologies relevant to PEG-modified Drugs (Recombinant Proteins-Polypeptides). It assesses the current state, advancements, and potential future developments in PEG-modified Drugs (Recombinant Proteins-Polypeptides) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the PEG-modified Drugs (Recombinant Proteins-Polypeptides) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
PEG-modified Drugs (Recombinant Proteins-Polypeptides) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Jinyouli
- Xin Rui Bai
- Shenlida
- Jin Saizeng
- Pegbin
- Fulaimei
- Aido
- Nonmyeloid Malignancy
- Slow Growth in Children
- Viral Hepatitis
- Adult Type 2 Diabetes
- Others
- Merck Sharp & Dohme
- Baxalta
- Amgen
- Roche
- UCB S.A.
- Enzon
- Horizon Pharma
- Biogen
- SunBio
- Qilu Pharmaceutical
- Changchun Genescience Pharmaceutical
- Xiamen Amoytop Biotech
- Jiangsu Hengrui Pharmaceuticals
- Hansoh Pharmaceuticak Group
- CSPC Baike (Shandong) Biopharmaceutical
- Xiamen Sano banger Biotechnology
- Lunan Pharmaceutical Group
- Xiamen Amoytop Biotech
- JenKem Technology
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe PEG-modified Drugs (Recombinant Proteins-Polypeptides) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PEG-modified Drugs (Recombinant Proteins-Polypeptides), with price, sales, revenue and global market share of PEG-modified Drugs (Recombinant Proteins-Polypeptides) from 2018 to 2023.
Chapter 3, the PEG-modified Drugs (Recombinant Proteins-Polypeptides) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PEG-modified Drugs (Recombinant Proteins-Polypeptides) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and PEG-modified Drugs (Recombinant Proteins-Polypeptides) market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of PEG-modified Drugs (Recombinant Proteins-Polypeptides).
Chapter 14 and 15, to describe PEG-modified Drugs (Recombinant Proteins-Polypeptides) sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of PEG-modified Drugs (Recombinant Proteins-Polypeptides)
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Jinyouli
1.3.3 Xin Rui Bai
1.3.4 Shenlida
1.3.5 Jin Saizeng
1.3.6 Pegbin
1.3.7 Fulaimei
1.3.8 Aido
1.4 Market Analysis by Application
1.4.1 Overview: Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Nonmyeloid Malignancy
1.4.3 Slow Growth in Children
1.4.4 Viral Hepatitis
1.4.5 Adult Type 2 Diabetes
1.4.6 Others
1.5 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size & Forecast
1.5.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018 & 2022 & 2029)
1.5.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (2018-2029)
1.5.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Merck Sharp & Dohme
2.1.1 Merck Sharp & Dohme Details
2.1.2 Merck Sharp & Dohme Major Business
2.1.3 Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.1.4 Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Merck Sharp & Dohme Recent Developments/Updates
2.2 Baxalta
2.2.1 Baxalta Details
2.2.2 Baxalta Major Business
2.2.3 Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.2.4 Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Baxalta Recent Developments/Updates
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business
2.3.3 Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.3.4 Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Amgen Recent Developments/Updates
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.4.4 Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Roche Recent Developments/Updates
2.5 UCB S.A.
2.5.1 UCB S.A. Details
2.5.2 UCB S.A. Major Business
2.5.3 UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.5.4 UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 UCB S.A. Recent Developments/Updates
2.6 Enzon
2.6.1 Enzon Details
2.6.2 Enzon Major Business
2.6.3 Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.6.4 Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Enzon Recent Developments/Updates
2.7 Horizon Pharma
2.7.1 Horizon Pharma Details
2.7.2 Horizon Pharma Major Business
2.7.3 Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.7.4 Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Horizon Pharma Recent Developments/Updates
2.8 Biogen
2.8.1 Biogen Details
2.8.2 Biogen Major Business
2.8.3 Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.8.4 Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Biogen Recent Developments/Updates
2.9 SunBio
2.9.1 SunBio Details
2.9.2 SunBio Major Business
2.9.3 SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.9.4 SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 SunBio Recent Developments/Updates
2.10 Qilu Pharmaceutical
2.10.1 Qilu Pharmaceutical Details
2.10.2 Qilu Pharmaceutical Major Business
2.10.3 Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.10.4 Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Qilu Pharmaceutical Recent Developments/Updates
2.11 Changchun Genescience Pharmaceutical
2.11.1 Changchun Genescience Pharmaceutical Details
2.11.2 Changchun Genescience Pharmaceutical Major Business
2.11.3 Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.11.4 Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Changchun Genescience Pharmaceutical Recent Developments/Updates
2.12 Xiamen Amoytop Biotech
2.12.1 Xiamen Amoytop Biotech Details
2.12.2 Xiamen Amoytop Biotech Major Business
2.12.3 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.12.4 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Xiamen Amoytop Biotech Recent Developments/Updates
2.13 Jiangsu Hengrui Pharmaceuticals
2.13.1 Jiangsu Hengrui Pharmaceuticals Details
2.13.2 Jiangsu Hengrui Pharmaceuticals Major Business
2.13.3 Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.13.4 Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
2.14 Hansoh Pharmaceuticak Group
2.14.1 Hansoh Pharmaceuticak Group Details
2.14.2 Hansoh Pharmaceuticak Group Major Business
2.14.3 Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.14.4 Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Hansoh Pharmaceuticak Group Recent Developments/Updates
2.15 CSPC Baike (Shandong) Biopharmaceutical
2.15.1 CSPC Baike (Shandong) Biopharmaceutical Details
2.15.2 CSPC Baike (Shandong) Biopharmaceutical Major Business
2.15.3 CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.15.4 CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 CSPC Baike (Shandong) Biopharmaceutical Recent Developments/Updates
2.16 Xiamen Sano banger Biotechnology
2.16.1 Xiamen Sano banger Biotechnology Details
2.16.2 Xiamen Sano banger Biotechnology Major Business
2.16.3 Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.16.4 Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Xiamen Sano banger Biotechnology Recent Developments/Updates
2.17 Lunan Pharmaceutical Group
2.17.1 Lunan Pharmaceutical Group Details
2.17.2 Lunan Pharmaceutical Group Major Business
2.17.3 Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.17.4 Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Lunan Pharmaceutical Group Recent Developments/Updates
2.18 Xiamen Amoytop Biotech
2.18.1 Xiamen Amoytop Biotech Details
2.18.2 Xiamen Amoytop Biotech Major Business
2.18.3 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.18.4 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Xiamen Amoytop Biotech Recent Developments/Updates
2.19 JenKem Technology
2.19.1 JenKem Technology Details
2.19.2 JenKem Technology Major Business
2.19.3 JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.19.4 JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 JenKem Technology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PEG-MODIFIED DRUGS (RECOMBINANT PROTEINS-POLYPEPTIDES) BY MANUFACTURER
3.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Manufacturer (2018-2023)
3.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Revenue by Manufacturer (2018-2023)
3.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of PEG-modified Drugs (Recombinant Proteins-Polypeptides) by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturer Market Share in 2022
3.4.2 Top 6 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturer Market Share in 2022
3.5 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Overall Company Footprint Analysis
3.5.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Region Footprint
3.5.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Type Footprint
3.5.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Region
4.1.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2029)
4.1.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2029)
4.1.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2018-2029)
4.2 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
4.3 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
4.4 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
4.5 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
4.6 Middle East and Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
5.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type (2018-2029)
5.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
6.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application (2018-2029)
6.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
7.2 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
7.3 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Country
7.3.1 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2029)
7.3.2 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
8.2 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
8.3 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Country
8.3.1 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2029)
8.3.2 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Region
9.3.1 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
10.2 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
10.3 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Country
10.3.1 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2029)
10.3.2 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Country
11.3.1 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Drivers
12.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Restraints
12.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of PEG-modified Drugs (Recombinant Proteins-Polypeptides) and Key Manufacturers
13.2 Manufacturing Costs Percentage of PEG-modified Drugs (Recombinant Proteins-Polypeptides)
13.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Process
13.4 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Distributors
14.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of PEG-modified Drugs (Recombinant Proteins-Polypeptides)
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Jinyouli
1.3.3 Xin Rui Bai
1.3.4 Shenlida
1.3.5 Jin Saizeng
1.3.6 Pegbin
1.3.7 Fulaimei
1.3.8 Aido
1.4 Market Analysis by Application
1.4.1 Overview: Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Nonmyeloid Malignancy
1.4.3 Slow Growth in Children
1.4.4 Viral Hepatitis
1.4.5 Adult Type 2 Diabetes
1.4.6 Others
1.5 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size & Forecast
1.5.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018 & 2022 & 2029)
1.5.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (2018-2029)
1.5.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Merck Sharp & Dohme
2.1.1 Merck Sharp & Dohme Details
2.1.2 Merck Sharp & Dohme Major Business
2.1.3 Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.1.4 Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Merck Sharp & Dohme Recent Developments/Updates
2.2 Baxalta
2.2.1 Baxalta Details
2.2.2 Baxalta Major Business
2.2.3 Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.2.4 Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Baxalta Recent Developments/Updates
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business
2.3.3 Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.3.4 Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Amgen Recent Developments/Updates
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.4.4 Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Roche Recent Developments/Updates
2.5 UCB S.A.
2.5.1 UCB S.A. Details
2.5.2 UCB S.A. Major Business
2.5.3 UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.5.4 UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 UCB S.A. Recent Developments/Updates
2.6 Enzon
2.6.1 Enzon Details
2.6.2 Enzon Major Business
2.6.3 Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.6.4 Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Enzon Recent Developments/Updates
2.7 Horizon Pharma
2.7.1 Horizon Pharma Details
2.7.2 Horizon Pharma Major Business
2.7.3 Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.7.4 Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Horizon Pharma Recent Developments/Updates
2.8 Biogen
2.8.1 Biogen Details
2.8.2 Biogen Major Business
2.8.3 Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.8.4 Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Biogen Recent Developments/Updates
2.9 SunBio
2.9.1 SunBio Details
2.9.2 SunBio Major Business
2.9.3 SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.9.4 SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 SunBio Recent Developments/Updates
2.10 Qilu Pharmaceutical
2.10.1 Qilu Pharmaceutical Details
2.10.2 Qilu Pharmaceutical Major Business
2.10.3 Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.10.4 Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Qilu Pharmaceutical Recent Developments/Updates
2.11 Changchun Genescience Pharmaceutical
2.11.1 Changchun Genescience Pharmaceutical Details
2.11.2 Changchun Genescience Pharmaceutical Major Business
2.11.3 Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.11.4 Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Changchun Genescience Pharmaceutical Recent Developments/Updates
2.12 Xiamen Amoytop Biotech
2.12.1 Xiamen Amoytop Biotech Details
2.12.2 Xiamen Amoytop Biotech Major Business
2.12.3 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.12.4 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Xiamen Amoytop Biotech Recent Developments/Updates
2.13 Jiangsu Hengrui Pharmaceuticals
2.13.1 Jiangsu Hengrui Pharmaceuticals Details
2.13.2 Jiangsu Hengrui Pharmaceuticals Major Business
2.13.3 Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.13.4 Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
2.14 Hansoh Pharmaceuticak Group
2.14.1 Hansoh Pharmaceuticak Group Details
2.14.2 Hansoh Pharmaceuticak Group Major Business
2.14.3 Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.14.4 Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Hansoh Pharmaceuticak Group Recent Developments/Updates
2.15 CSPC Baike (Shandong) Biopharmaceutical
2.15.1 CSPC Baike (Shandong) Biopharmaceutical Details
2.15.2 CSPC Baike (Shandong) Biopharmaceutical Major Business
2.15.3 CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.15.4 CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 CSPC Baike (Shandong) Biopharmaceutical Recent Developments/Updates
2.16 Xiamen Sano banger Biotechnology
2.16.1 Xiamen Sano banger Biotechnology Details
2.16.2 Xiamen Sano banger Biotechnology Major Business
2.16.3 Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.16.4 Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Xiamen Sano banger Biotechnology Recent Developments/Updates
2.17 Lunan Pharmaceutical Group
2.17.1 Lunan Pharmaceutical Group Details
2.17.2 Lunan Pharmaceutical Group Major Business
2.17.3 Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.17.4 Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Lunan Pharmaceutical Group Recent Developments/Updates
2.18 Xiamen Amoytop Biotech
2.18.1 Xiamen Amoytop Biotech Details
2.18.2 Xiamen Amoytop Biotech Major Business
2.18.3 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.18.4 Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Xiamen Amoytop Biotech Recent Developments/Updates
2.19 JenKem Technology
2.19.1 JenKem Technology Details
2.19.2 JenKem Technology Major Business
2.19.3 JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
2.19.4 JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 JenKem Technology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PEG-MODIFIED DRUGS (RECOMBINANT PROTEINS-POLYPEPTIDES) BY MANUFACTURER
3.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Manufacturer (2018-2023)
3.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Revenue by Manufacturer (2018-2023)
3.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of PEG-modified Drugs (Recombinant Proteins-Polypeptides) by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturer Market Share in 2022
3.4.2 Top 6 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturer Market Share in 2022
3.5 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Overall Company Footprint Analysis
3.5.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Region Footprint
3.5.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Type Footprint
3.5.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Region
4.1.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2029)
4.1.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2029)
4.1.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2018-2029)
4.2 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
4.3 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
4.4 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
4.5 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
4.6 Middle East and Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
5.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type (2018-2029)
5.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
6.2 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application (2018-2029)
6.3 Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
7.2 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
7.3 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Country
7.3.1 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2029)
7.3.2 North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
8.2 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
8.3 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Country
8.3.1 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2029)
8.3.2 Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Region
9.3.1 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
10.2 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
10.3 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Country
10.3.1 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2029)
10.3.2 South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Size by Country
11.3.1 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Drivers
12.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Restraints
12.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of PEG-modified Drugs (Recombinant Proteins-Polypeptides) and Key Manufacturers
13.2 Manufacturing Costs Percentage of PEG-modified Drugs (Recombinant Proteins-Polypeptides)
13.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Process
13.4 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Distributors
14.3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Merck Sharp & Dohme Basic Information, Manufacturing Base and Competitors
Table 4. Merck Sharp & Dohme Major Business
Table 5. Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 6. Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Merck Sharp & Dohme Recent Developments/Updates
Table 8. Baxalta Basic Information, Manufacturing Base and Competitors
Table 9. Baxalta Major Business
Table 10. Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 11. Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Baxalta Recent Developments/Updates
Table 13. Amgen Basic Information, Manufacturing Base and Competitors
Table 14. Amgen Major Business
Table 15. Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 16. Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Amgen Recent Developments/Updates
Table 18. Roche Basic Information, Manufacturing Base and Competitors
Table 19. Roche Major Business
Table 20. Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 21. Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Roche Recent Developments/Updates
Table 23. UCB S.A. Basic Information, Manufacturing Base and Competitors
Table 24. UCB S.A. Major Business
Table 25. UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 26. UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. UCB S.A. Recent Developments/Updates
Table 28. Enzon Basic Information, Manufacturing Base and Competitors
Table 29. Enzon Major Business
Table 30. Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 31. Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Enzon Recent Developments/Updates
Table 33. Horizon Pharma Basic Information, Manufacturing Base and Competitors
Table 34. Horizon Pharma Major Business
Table 35. Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 36. Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Horizon Pharma Recent Developments/Updates
Table 38. Biogen Basic Information, Manufacturing Base and Competitors
Table 39. Biogen Major Business
Table 40. Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 41. Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Biogen Recent Developments/Updates
Table 43. SunBio Basic Information, Manufacturing Base and Competitors
Table 44. SunBio Major Business
Table 45. SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 46. SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. SunBio Recent Developments/Updates
Table 48. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 49. Qilu Pharmaceutical Major Business
Table 50. Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 51. Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Qilu Pharmaceutical Recent Developments/Updates
Table 53. Changchun Genescience Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 54. Changchun Genescience Pharmaceutical Major Business
Table 55. Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 56. Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Changchun Genescience Pharmaceutical Recent Developments/Updates
Table 58. Xiamen Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 59. Xiamen Amoytop Biotech Major Business
Table 60. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 61. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Xiamen Amoytop Biotech Recent Developments/Updates
Table 63. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 64. Jiangsu Hengrui Pharmaceuticals Major Business
Table 65. Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 66. Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 68. Hansoh Pharmaceuticak Group Basic Information, Manufacturing Base and Competitors
Table 69. Hansoh Pharmaceuticak Group Major Business
Table 70. Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 71. Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Hansoh Pharmaceuticak Group Recent Developments/Updates
Table 73. CSPC Baike (Shandong) Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 74. CSPC Baike (Shandong) Biopharmaceutical Major Business
Table 75. CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 76. CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. CSPC Baike (Shandong) Biopharmaceutical Recent Developments/Updates
Table 78. Xiamen Sano banger Biotechnology Basic Information, Manufacturing Base and Competitors
Table 79. Xiamen Sano banger Biotechnology Major Business
Table 80. Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 81. Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. Xiamen Sano banger Biotechnology Recent Developments/Updates
Table 83. Lunan Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 84. Lunan Pharmaceutical Group Major Business
Table 85. Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 86. Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Lunan Pharmaceutical Group Recent Developments/Updates
Table 88. Xiamen Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 89. Xiamen Amoytop Biotech Major Business
Table 90. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 91. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Xiamen Amoytop Biotech Recent Developments/Updates
Table 93. JenKem Technology Basic Information, Manufacturing Base and Competitors
Table 94. JenKem Technology Major Business
Table 95. JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 96. JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. JenKem Technology Recent Developments/Updates
Table 98. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 99. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Revenue by Manufacturer (2018-2023) & (USD Million)
Table 100. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 101. Market Position of Manufacturers in PEG-modified Drugs (Recombinant Proteins-Polypeptides), (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 102. Head Office and PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Site of Key Manufacturer
Table 103. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Type Footprint
Table 104. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Application Footprint
Table 105. PEG-modified Drugs (Recombinant Proteins-Polypeptides) New Market Entrants and Barriers to Market Entry
Table 106. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Mergers, Acquisition, Agreements, and Collaborations
Table 107. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2023) & (K Units)
Table 108. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2024-2029) & (K Units)
Table 109. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2023) & (USD Million)
Table 110. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2024-2029) & (USD Million)
Table 111. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2018-2023) & (US$/Unit)
Table 112. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2024-2029) & (US$/Unit)
Table 113. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type (2018-2023) & (USD Million)
Table 116. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type (2024-2029) & (USD Million)
Table 117. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2023) & (US$/Unit)
Table 118. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2024-2029) & (US$/Unit)
Table 119. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 120. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 121. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application (2018-2023) & (USD Million)
Table 122. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application (2024-2029) & (USD Million)
Table 123. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2023) & (US$/Unit)
Table 124. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2024-2029) & (US$/Unit)
Table 125. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 126. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 127. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 128. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 129. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2023) & (K Units)
Table 130. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2024-2029) & (K Units)
Table 131. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2023) & (USD Million)
Table 132. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2024-2029) & (USD Million)
Table 133. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 134. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 135. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 136. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 137. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2023) & (K Units)
Table 138. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2024-2029) & (K Units)
Table 139. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2023) & (USD Million)
Table 140. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2024-2029) & (USD Million)
Table 141. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 142. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 143. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 144. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 145. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2023) & (K Units)
Table 146. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2024-2029) & (K Units)
Table 147. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2023) & (USD Million)
Table 148. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2024-2029) & (USD Million)
Table 149. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 150. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 151. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 152. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 153. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2023) & (K Units)
Table 154. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2024-2029) & (K Units)
Table 155. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2023) & (USD Million)
Table 156. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2024-2029) & (USD Million)
Table 157. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 158. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 159. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 160. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 161. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2023) & (K Units)
Table 162. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2024-2029) & (K Units)
Table 163. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2023) & (USD Million)
Table 164. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2024-2029) & (USD Million)
Table 165. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Raw Material
Table 166. Key Manufacturers of PEG-modified Drugs (Recombinant Proteins-Polypeptides) Raw Materials
Table 167. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Distributors
Table 168. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Customers
Table 1. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Merck Sharp & Dohme Basic Information, Manufacturing Base and Competitors
Table 4. Merck Sharp & Dohme Major Business
Table 5. Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 6. Merck Sharp & Dohme PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Merck Sharp & Dohme Recent Developments/Updates
Table 8. Baxalta Basic Information, Manufacturing Base and Competitors
Table 9. Baxalta Major Business
Table 10. Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 11. Baxalta PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Baxalta Recent Developments/Updates
Table 13. Amgen Basic Information, Manufacturing Base and Competitors
Table 14. Amgen Major Business
Table 15. Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 16. Amgen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Amgen Recent Developments/Updates
Table 18. Roche Basic Information, Manufacturing Base and Competitors
Table 19. Roche Major Business
Table 20. Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 21. Roche PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Roche Recent Developments/Updates
Table 23. UCB S.A. Basic Information, Manufacturing Base and Competitors
Table 24. UCB S.A. Major Business
Table 25. UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 26. UCB S.A. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. UCB S.A. Recent Developments/Updates
Table 28. Enzon Basic Information, Manufacturing Base and Competitors
Table 29. Enzon Major Business
Table 30. Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 31. Enzon PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Enzon Recent Developments/Updates
Table 33. Horizon Pharma Basic Information, Manufacturing Base and Competitors
Table 34. Horizon Pharma Major Business
Table 35. Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 36. Horizon Pharma PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Horizon Pharma Recent Developments/Updates
Table 38. Biogen Basic Information, Manufacturing Base and Competitors
Table 39. Biogen Major Business
Table 40. Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 41. Biogen PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Biogen Recent Developments/Updates
Table 43. SunBio Basic Information, Manufacturing Base and Competitors
Table 44. SunBio Major Business
Table 45. SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 46. SunBio PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. SunBio Recent Developments/Updates
Table 48. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 49. Qilu Pharmaceutical Major Business
Table 50. Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 51. Qilu Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Qilu Pharmaceutical Recent Developments/Updates
Table 53. Changchun Genescience Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 54. Changchun Genescience Pharmaceutical Major Business
Table 55. Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 56. Changchun Genescience Pharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Changchun Genescience Pharmaceutical Recent Developments/Updates
Table 58. Xiamen Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 59. Xiamen Amoytop Biotech Major Business
Table 60. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 61. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Xiamen Amoytop Biotech Recent Developments/Updates
Table 63. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 64. Jiangsu Hengrui Pharmaceuticals Major Business
Table 65. Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 66. Jiangsu Hengrui Pharmaceuticals PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 68. Hansoh Pharmaceuticak Group Basic Information, Manufacturing Base and Competitors
Table 69. Hansoh Pharmaceuticak Group Major Business
Table 70. Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 71. Hansoh Pharmaceuticak Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Hansoh Pharmaceuticak Group Recent Developments/Updates
Table 73. CSPC Baike (Shandong) Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 74. CSPC Baike (Shandong) Biopharmaceutical Major Business
Table 75. CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 76. CSPC Baike (Shandong) Biopharmaceutical PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. CSPC Baike (Shandong) Biopharmaceutical Recent Developments/Updates
Table 78. Xiamen Sano banger Biotechnology Basic Information, Manufacturing Base and Competitors
Table 79. Xiamen Sano banger Biotechnology Major Business
Table 80. Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 81. Xiamen Sano banger Biotechnology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. Xiamen Sano banger Biotechnology Recent Developments/Updates
Table 83. Lunan Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 84. Lunan Pharmaceutical Group Major Business
Table 85. Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 86. Lunan Pharmaceutical Group PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Lunan Pharmaceutical Group Recent Developments/Updates
Table 88. Xiamen Amoytop Biotech Basic Information, Manufacturing Base and Competitors
Table 89. Xiamen Amoytop Biotech Major Business
Table 90. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 91. Xiamen Amoytop Biotech PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Xiamen Amoytop Biotech Recent Developments/Updates
Table 93. JenKem Technology Basic Information, Manufacturing Base and Competitors
Table 94. JenKem Technology Major Business
Table 95. JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Product and Services
Table 96. JenKem Technology PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. JenKem Technology Recent Developments/Updates
Table 98. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 99. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Revenue by Manufacturer (2018-2023) & (USD Million)
Table 100. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 101. Market Position of Manufacturers in PEG-modified Drugs (Recombinant Proteins-Polypeptides), (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 102. Head Office and PEG-modified Drugs (Recombinant Proteins-Polypeptides) Production Site of Key Manufacturer
Table 103. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Type Footprint
Table 104. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market: Company Product Application Footprint
Table 105. PEG-modified Drugs (Recombinant Proteins-Polypeptides) New Market Entrants and Barriers to Market Entry
Table 106. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Mergers, Acquisition, Agreements, and Collaborations
Table 107. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2023) & (K Units)
Table 108. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2024-2029) & (K Units)
Table 109. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2023) & (USD Million)
Table 110. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2024-2029) & (USD Million)
Table 111. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2018-2023) & (US$/Unit)
Table 112. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Region (2024-2029) & (US$/Unit)
Table 113. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type (2018-2023) & (USD Million)
Table 116. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type (2024-2029) & (USD Million)
Table 117. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2023) & (US$/Unit)
Table 118. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2024-2029) & (US$/Unit)
Table 119. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 120. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 121. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application (2018-2023) & (USD Million)
Table 122. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application (2024-2029) & (USD Million)
Table 123. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2023) & (US$/Unit)
Table 124. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2024-2029) & (US$/Unit)
Table 125. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 126. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 127. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 128. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 129. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2023) & (K Units)
Table 130. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2024-2029) & (K Units)
Table 131. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2023) & (USD Million)
Table 132. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2024-2029) & (USD Million)
Table 133. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 134. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 135. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 136. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 137. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2023) & (K Units)
Table 138. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2024-2029) & (K Units)
Table 139. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2023) & (USD Million)
Table 140. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2024-2029) & (USD Million)
Table 141. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 142. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 143. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 144. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 145. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2023) & (K Units)
Table 146. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2024-2029) & (K Units)
Table 147. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2023) & (USD Million)
Table 148. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2024-2029) & (USD Million)
Table 149. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 150. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 151. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 152. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 153. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2018-2023) & (K Units)
Table 154. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Country (2024-2029) & (K Units)
Table 155. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2018-2023) & (USD Million)
Table 156. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Country (2024-2029) & (USD Million)
Table 157. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2018-2023) & (K Units)
Table 158. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Type (2024-2029) & (K Units)
Table 159. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2018-2023) & (K Units)
Table 160. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Application (2024-2029) & (K Units)
Table 161. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2018-2023) & (K Units)
Table 162. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity by Region (2024-2029) & (K Units)
Table 163. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2018-2023) & (USD Million)
Table 164. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Region (2024-2029) & (USD Million)
Table 165. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Raw Material
Table 166. Key Manufacturers of PEG-modified Drugs (Recombinant Proteins-Polypeptides) Raw Materials
Table 167. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Distributors
Table 168. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Typical Customers
LIST OF FIGURES
Figure 1. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Picture
Figure 2. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Type in 2022
Figure 4. Jinyouli Examples
Figure 5. Xin Rui Bai Examples
Figure 6. Shenlida Examples
Figure 7. Jin Saizeng Examples
Figure 8. Pegbin Examples
Figure 9. Fulaimei Examples
Figure 10. Aido Examples
Figure 11. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 12. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Application in 2022
Figure 13. Nonmyeloid Malignancy Examples
Figure 14. Slow Growth in Children Examples
Figure 15. Viral Hepatitis Examples
Figure 16. Adult Type 2 Diabetes Examples
Figure 17. Others Examples
Figure 18. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 19. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 20. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (2018-2029) & (K Units)
Figure 21. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price (2018-2029) & (US$/Unit)
Figure 22. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Manufacturer in 2022
Figure 23. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Manufacturer in 2022
Figure 24. Producer Shipments of PEG-modified Drugs (Recombinant Proteins-Polypeptides) by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 25. Top 3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturer (Consumption Value) Market Share in 2022
Figure 26. Top 6 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturer (Consumption Value) Market Share in 2022
Figure 27. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Region (2018-2029)
Figure 28. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Region (2018-2029)
Figure 29. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 30. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 31. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 32. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 33. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 34. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 35. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Type (2018-2029)
Figure 36. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2029) & (US$/Unit)
Figure 37. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 38. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Application (2018-2029)
Figure 39. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2029) & (US$/Unit)
Figure 40. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 41. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 42. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Country (2018-2029)
Figure 43. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Country (2018-2029)
Figure 44. United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Canada PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Mexico PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 48. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 49. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Country (2018-2029)
Figure 50. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Country (2018-2029)
Figure 51. Germany PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. France PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. United Kingdom PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Russia PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Italy PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 57. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 58. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Region (2018-2029)
Figure 59. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Region (2018-2029)
Figure 60. China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Korea PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. India PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Southeast Asia PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Australia PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 67. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 68. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Country (2018-2029)
Figure 69. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Country (2018-2029)
Figure 70. Brazil PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Argentina PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 73. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 74. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Region (2018-2029)
Figure 75. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Region (2018-2029)
Figure 76. Turkey PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Egypt PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. Saudi Arabia PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 79. South Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 80. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Drivers
Figure 81. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Restraints
Figure 82. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Trends
Figure 83. Porters Five Forces Analysis
Figure 84. Manufacturing Cost Structure Analysis of PEG-modified Drugs (Recombinant Proteins-Polypeptides) in 2022
Figure 85. Manufacturing Process Analysis of PEG-modified Drugs (Recombinant Proteins-Polypeptides)
Figure 86. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industrial Chain
Figure 87. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 88. Direct Channel Pros & Cons
Figure 89. Indirect Channel Pros & Cons
Figure 90. Methodology
Figure 91. Research Process and Data Source
Figure 1. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Picture
Figure 2. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Type in 2022
Figure 4. Jinyouli Examples
Figure 5. Xin Rui Bai Examples
Figure 6. Shenlida Examples
Figure 7. Jin Saizeng Examples
Figure 8. Pegbin Examples
Figure 9. Fulaimei Examples
Figure 10. Aido Examples
Figure 11. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 12. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Application in 2022
Figure 13. Nonmyeloid Malignancy Examples
Figure 14. Slow Growth in Children Examples
Figure 15. Viral Hepatitis Examples
Figure 16. Adult Type 2 Diabetes Examples
Figure 17. Others Examples
Figure 18. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 19. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 20. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity (2018-2029) & (K Units)
Figure 21. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price (2018-2029) & (US$/Unit)
Figure 22. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Manufacturer in 2022
Figure 23. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Manufacturer in 2022
Figure 24. Producer Shipments of PEG-modified Drugs (Recombinant Proteins-Polypeptides) by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 25. Top 3 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturer (Consumption Value) Market Share in 2022
Figure 26. Top 6 PEG-modified Drugs (Recombinant Proteins-Polypeptides) Manufacturer (Consumption Value) Market Share in 2022
Figure 27. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Region (2018-2029)
Figure 28. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Region (2018-2029)
Figure 29. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 30. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 31. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 32. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 33. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value (2018-2029) & (USD Million)
Figure 34. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 35. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Type (2018-2029)
Figure 36. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Type (2018-2029) & (US$/Unit)
Figure 37. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 38. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Application (2018-2029)
Figure 39. Global PEG-modified Drugs (Recombinant Proteins-Polypeptides) Average Price by Application (2018-2029) & (US$/Unit)
Figure 40. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 41. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 42. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Country (2018-2029)
Figure 43. North America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Country (2018-2029)
Figure 44. United States PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Canada PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Mexico PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 48. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 49. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Country (2018-2029)
Figure 50. Europe PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Country (2018-2029)
Figure 51. Germany PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. France PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. United Kingdom PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Russia PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Italy PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 57. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 58. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Region (2018-2029)
Figure 59. Asia-Pacific PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Region (2018-2029)
Figure 60. China PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Japan PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Korea PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. India PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Southeast Asia PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Australia PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 67. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 68. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Country (2018-2029)
Figure 69. South America PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Country (2018-2029)
Figure 70. Brazil PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Argentina PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Type (2018-2029)
Figure 73. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Application (2018-2029)
Figure 74. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Sales Quantity Market Share by Region (2018-2029)
Figure 75. Middle East & Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value Market Share by Region (2018-2029)
Figure 76. Turkey PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Egypt PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. Saudi Arabia PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 79. South Africa PEG-modified Drugs (Recombinant Proteins-Polypeptides) Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 80. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Drivers
Figure 81. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Restraints
Figure 82. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Market Trends
Figure 83. Porters Five Forces Analysis
Figure 84. Manufacturing Cost Structure Analysis of PEG-modified Drugs (Recombinant Proteins-Polypeptides) in 2022
Figure 85. Manufacturing Process Analysis of PEG-modified Drugs (Recombinant Proteins-Polypeptides)
Figure 86. PEG-modified Drugs (Recombinant Proteins-Polypeptides) Industrial Chain
Figure 87. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 88. Direct Channel Pros & Cons
Figure 89. Indirect Channel Pros & Cons
Figure 90. Methodology
Figure 91. Research Process and Data Source
